City Holding Co. boosted its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 20.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 15,836 shares of the biopharmaceutical company’s stock after buying an additional 2,695 shares during the period. City Holding Co.’s holdings in Gilead Sciences were worth $1,253,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of GILD. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock valued at $2,220,410,000 after buying an additional 1,023,299 shares during the period. BlackRock Fund Advisors increased its stake in Gilead Sciences by 2.6% in the second quarter. BlackRock Fund Advisors now owns 24,369,287 shares of the biopharmaceutical company’s stock valued at $2,032,886,000 after buying an additional 612,544 shares during the period. Capital World Investors increased its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares during the period. Alliancebernstein L.P. increased its stake in Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock valued at $1,113,383,000 after buying an additional 1,942,138 shares during the period. Finally, Parnassus Investments CA increased its stake in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the period. 73.59% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.44% on Tuesday, hitting $74.87. The stock has a market capitalization of $98.64 billion, a P/E ratio of 6.92 and a beta of 1.25. The firm’s 50 day moving average is $74.54 and its 200-day moving average is $80.07. Gilead Sciences Inc. has a 12-month low of $71.39 and a 12-month high of $107.38.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. During the same quarter last year, the company posted $3.22 EPS. Gilead Sciences’s quarterly revenue was down 9.6% on a year-over-year basis. Equities research analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 annualized dividend and a dividend yield of 2.51%. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

TRADEMARK VIOLATION WARNING: This story was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The original version of this story can be read at http://www.financial-market-news.com/gilead-sciences-inc-gild-shares-bought-by-city-holding-co/1209523/.

Several equities research analysts have commented on the company. Piper Jaffray Cos. set a $108.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, August 21st. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Sunday, November 6th. Cowen and Company set a $120.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, October 23rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $91.00 price target on shares of Gilead Sciences in a report on Thursday, September 22nd. Ten equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $97.90.

In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the sale, the executive vice president now owns 132,964 shares in the company, valued at $10,881,773.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 100,000 shares of the stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the sale, the insider now owns 3,287,810 shares of the company’s stock, valued at approximately $254,739,518.80. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.